Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial Lipocine Inc.'s Phase 3 trial results for LPCN 1154 in postpartum depression reveal mixed efficacy and a well-tolerated safety profile among participants.

Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Long-Term Benefits of mHealth Consultation on Postpartum Depression A recent study highlights significant long-term benefits of online healthcare consultations in reducing postpartum depression risks by 32%.

Long-Term Benefits of mHealth Consultation on Postpartum Depression #Japan #Yokohama #postpartum_depression #Yokohama_City #mHealth_Consultation

Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment Lipocine Inc. completes the last patient visit in the Phase 3 trial of LPCN 1154, an oral treatment for postpartum depression (PPD), showing positive safety results.

Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression Lipocine has finished participant enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. Initial results are promising.

Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review Lipocine Inc. announced the successful completion of an independent safety review for LPCN 1154 in a Phase 3 trial targeting postpartum depression, reinforcing confidence in its efficacy.

Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression Lipocine Inc. shares an update on its Phase 3 trial of LPCN 1154 for postpartum depression, with promising enrollment and safety review plans.

Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025 Join Lipocine's virtual R&D investor event on July 9, 2025, to explore LPCN 1154's potential in treating postpartum depression, alongside expert insights.

Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025 #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression Lipocine Inc. has launched a Phase 3 trial for LPCN 1154, aimed at treating postpartum depression through effective oral delivery.

Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Stork Club Unveils Pioneering Care for Postpartum Depression to Aid Working Mothers Stork Club has launched an innovative digital program addressing postpartum depression, offering vital support for working mothers and improving workplace conditions.

Stork Club Unveils Pioneering Care for Postpartum Depression to Aid Working Mothers #United_States #San_Francisco #Stork_Club #working_mothers #postpartum_depression

Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression Lipocine's latest regulatory guidance suggests further safety and efficacy trials for LPCN 1154, aiming to address postpartum depression in women rapidly.

Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression